# Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA

Source: https://onco.cc/trials/nct05797077/  
OnCo record `nct05797077` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine in colorectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, now recruiting.

## Summary

Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA is a phase 3, randomised interventional study registered as NCT05797077 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 346 participants, started 2023-02-20 and due to reach its primary completion in 2029-02-20. Interventions recorded: Colorectal resection surgery.; FOLFOX chemotherapy regimen; Capecitabine. Conditions listed: Colorectal Cancer; Liver Metastases; Circulating Tumor Cell; Cancer, Therapy-Related. Primary outcome: 3-years Progression Free Survival; 5-years Progression Free Survival. Colorectal eligibility wording from the registry: "Patients with liver metastatic colorectal cancer who have undergone R0 resection based on MDT evaluation (including patients whose metastases have been treated with ablation achieving similar R0 resection effect);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05797077
- Phase: 3
- Setting: Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA: a Multicenter, Randomized, Controlled, Phase III Clinical Trial.
- Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- Enrolled: 346

## Sources

- ClinicalTrials.gov NCT05797077: https://clinicaltrials.gov/study/NCT05797077

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05797077.json